Pharmacokinetic Study of CXB909 in Healthy Male Subjects

This study is not yet open for participant recruitment.

Verified January 2012 by CeNeRx BioPharma Inc.

Sponsor:

Information provided by (Responsible Party):

CeNeRx BioPharma Inc.

ClinicalTrials.gov Identifier:

NCT01505907

First received: January 5, 2012

Last updated: January 6, 2012

Last verified: January 2012

History of Changes

Tracking Information
First Received Date ^ICMJE	January 5, 2012
Last Updated Date	January 6, 2012
Start Date ^ICMJE	December 2012
Estimated Primary Completion Date	December 2013 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: January 6, 2012)	Pharmacokinetic Parameters [ Time Frame: 1 Week ] [ Designated as safety issue: No ] The PK parameters to be determined will include: Tmax, t1/2, Cmax, AUClast, AUCinf, Vd/F and CL/F.
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT01505907 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: January 6, 2012)	Safety [ Time Frame: 1 Week ] [ Designated as safety issue: Yes ] Descriptive statistics will be reported for adverse events; systolic and diastolic blood pressures; pulse; the respiration rate; QTC, PR, and QRS intervals; and the laboratory parameters. QTC will be calculated using both the Bazett and Fridericia corrections.
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Pharmacokinetic Study of CXB909 in Healthy Male Subjects
Official Title ^ICMJE	Phase I, Randomized, Double-Blind, Placebo Controlled, Dose Escalation,Single Dose, Safety, Tolerance, and Pharmacokinetic Study of CXB909 in Healthy Male Volunteers
Brief Summary	The primary objective of this dose escalation study is to examine the safety, tolerability, and pharmacokinetic properties of single-doses of CXB909, compared to placebo, in healthy male volunteers. This study may evaluate five (5) dose levels of CXB909; however, the number of dose levels, as well as the dosages, may be adjusted after evaluation of in-study analysis of the safety, tolerability, and pharmacokinetic data. This study will attempt to identify the maximum tolerated single dose of CXB909.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 1 Phase 2
Study Design ^ICMJE	Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Caregiver, Investigator)
Condition ^ICMJE	Healthy
Intervention ^ICMJE	Drug: CXB909 CXB909
Study Arm (s)	Experimental: CXB909 15mg CXB909 15mg Intervention: Drug: CXB909 Experimental: CXB909 30mg Intervention: Drug: CXB909 Experimental: CXB909 60mg Intervention: Drug: CXB909 Experimental: CXB909 120mg Dose Intervention: Drug: CXB909 Experimental: CXB909 250mg Intervention: Drug: CXB909
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Not yet recruiting
Estimated Enrollment ^ICMJE	40
Estimated Completion Date	December 2014
Estimated Primary Completion Date	December 2013 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Male, 18 to 50 years of age. Able to read, understand, and provide written/dated informed consent before screening in the study, and must be willing to comply with all study procedures. In good general health as ascertained by thorough medical history, physical examination (PE)including measurement of supine and standing vital signs, clinical laboratory studies, and 12-lead electrocardiogram (EKG). Body Mass Index (BMI) > 21 and < 30. Willing and able to be confined to the clinical research unit as required by the protocol. Exclusion Criteria: Presence of a significant acute or chronic medical disorder that might complicate evaluation of the study drug such as: Any cardiovascular or cardiac condition. Supine SBP≥145 mmHg and/or DBP ≥90 mmHg at Screening. Diabetes mellitus. Malignancy and/or chemotherapy within two years of screening, other than basal cell carcinoma. Malignancies more than two years prior may not preclude participation; however, must be reviewed on a case-by-case basis by the CeNeRx BioPharma, Inc., medical monitor. Known or suspected hypersensitivity to CXB909. Any gastrointestinal disease or digestive disorder, neurological, pulmonary, hepatic, renal, hematologic, endocrine and/or metabolic disease or disorder. Current or past psychiatric illness. Use of any prescription medications within 14 days of study drug administration. Use of any over-the-counter (OTC) medication within seven days of study drug administration (including herbal remedies). History of substance abuse, including alcohol abuse as defined by DSM-IV criteria,within the past 12 months. Current use of tobacco products or any nicotine-containing products (e.g., gum, patch)for the prior three months. Consumption of alcohol or caffeine/xanthine-containing drinks or foods within 72 hours of dosing on Day 1 (including any type of wines, caffeinated or decaffeinated herbal tea, and grapefruit products (e.g., fresh, canned, or frozen), Seville oranges and pomelos). Abnormal screening medical/physical examination, unless the abnormality is considered unlikely to be affected by study participation, or confound interpretation of safety data. A clinically significant clinical laboratory or EKG abnormality at screening; includes any of the following: aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphate (ALP) >2.0 x the upper limit of normal (ULN); total bilirubin >1.5 x the ULN;serum creatinine >1.5 x the ULN; blood urea nitrogen (BUN) >1.5 x the ULN; and thyroid stimulating hormone (TSH) and/or free thyroxine (T4) outside of the normal limits. Test positive for: Urine cannabinoids, cocaine, amphetamines, barbiturates, opiates or benzodiazepines, serum alcohol, hepatitis B or C, or nicotine use. HIV/AIDS. Participation in a clinical investigation within the last 45 days of screening. Any other condition which, in the investigator's opinion, may place the subject at greater than normal risk of developing complications. Donation of any blood product (one pint or greater) within the previous eight weeks of screening. Planning to donate any blood product within eight weeks of end of study.
Gender	Male
Ages	18 Years to 50 Years
Accepts Healthy Volunteers	Yes
Contacts ^ICMJE	Not Provided
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT01505907
Other Study ID Numbers ^ICMJE	CXB909-100
Has Data Monitoring Committee	Yes
Responsible Party	CeNeRx BioPharma Inc.
Study Sponsor ^ICMJE	CeNeRx BioPharma Inc.
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	CeNeRx BioPharma Inc.
Verification Date	January 2012
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top